Dolutegravir
- Generic Name
- Dolutegravir
- Brand Names
- Dovato, Juluca, Tivicay, Triumeq
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19F2N3O5
- CAS Number
- 1051375-16-6
- Unique Ingredient Identifier
- DKO1W9H7M1
- Background
Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013. On Nove...
- Indication
Dolutegravir is indicated in combination with other antiretroviral agents for the treatment of patients with HIV-1 infection that comply with the characteristics of being adults or children aged 12 years and older and present at least a weight of 40 kg. The FDA combination therapy approval of dolutegravir and rilpivirine is indicated for adults with HIV-1 in...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Nucleosides And Darunavir/Dolutegravir In Africa
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 465
- Registration Number
- NCT03988452
- Locations
- 🇺🇬
Infectious Diseases Institute, Kampala, Uganda
Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Radboud University Medical Center
- Registration Number
- NCT03813979
Effect on HIV Medications on EPC Cells
- Conditions
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Sabyasachi Sen
- Target Recruit Count
- 22
- Registration Number
- NCT03782142
- Locations
- 🇺🇸
The GW Medical Faculty Associates, Washington, District of Columbia, United States
Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs
- Conditions
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Viriom
- Target Recruit Count
- 36
- Registration Number
- NCT03706898
- Locations
- 🇷🇺
Regional State Budgetary Healthcare Institution "Smolensk Regional Clinical Hospital", Smolensk, Russian Federation
Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana
- Conditions
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 148
- Registration Number
- NCT03336346
- Locations
- 🇧🇼
Botswana-UPenn Partnership, Gaborone, Botswana
Dolutegravir in Pregnant HIV Mothers and Their Neonates
- Conditions
- Interventions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 268
- Registration Number
- NCT03249181
- Locations
- 🇺🇬
Infectious Diseases Institute, Kampala, Uganda
🇿🇦University of Cape Town, Cape Town, Western Cape, South Africa
A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- St. Stephens Clinical Research
- Target Recruit Count
- 16
- Registration Number
- NCT03199690
ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Professor Francois Venter
- Target Recruit Count
- 1110
- Registration Number
- NCT03122262
- Locations
- 🇿🇦
Wits RHI Yeoville Clinic, Johannesburg, Gauteng, South Africa
🇿🇦Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa
🇿🇦Shandukani Research Centre, Johannesburg, Gauteng, South Africa
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 154
- Registration Number
- NCT03078556
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2022-11-21
- Target Recruit Count
- 643
- Registration Number
- NCT03048422
- Locations
- 🇧🇼
Molepolole CRS, Gaborone, Botswana
🇹🇭Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand
🇿🇼St Mary's CRS, Chitungwiza, Zimbabwe
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.